Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Holding AG Announces Earnings Guidance for the Full Year 2021

07/22/2021 | 01:00am EDT

Roche Holding AG announced earnings guidance for the full year 2021. The company announced that Despite the continued strong impact of biosimilars, sales are expected to grow in the low- to mid-single digit range, at constant exchange rates. Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates.


ę S&P Capital IQ 2021
All news about ROCHE HOLDING AG
01:00aPRESS RELEASE : Roche launches three respiratory -2-
DJ
01:00aROCHE : launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to..
AQ
01:00aPRESS RELEASE : Roche launches three respiratory test panels on cobas 6800/8800 Systems in..
DJ
09/21ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-Stage Lun..
AQ
09/20ROCHE : Booster programme welcome but plans must be in place for boosters for all vaccinat..
AQ
09/20ROCHE : Says Phase III Trial of Tecentriq Showed Reduction in Lung Cancer Recurrence, Deat..
MT
09/20ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-stage Lun..
BU
09/20ROCHE : New Phase III data support the benefit of Roche's Tecentriq in early-stage lung ca..
AQ
09/20PRESS RELEASE : New Phase III data support the -2-
DJ
09/20PRESS RELEASE : New Phase III data support the benefit of Roche's Tecentriq in early-stage..
DJ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 435 M 66 399 M 66 399 M
Net income 2021 14 639 M 15 821 M 15 821 M
Net cash 2021 4 891 M 5 286 M 5 286 M
P/E ratio 2021 19,4x
Yield 2021 2,77%
Capitalization 297 B 322 B 321 B
EV / Sales 2021 4,76x
EV / Sales 2022 4,62x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 339,35 CHF
Average target price 384,23 CHF
Spread / Average Target 13,2%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG9.82%321 584
JOHNSON & JOHNSON4.54%431 227
PFIZER, INC.20.08%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY36.32%210 000
ABBVIE INC.0.00%188 027